Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › CD19-directed chimeric antigen receptors and uses thereof in immunotherapy

CD19-directed chimeric antigen receptors and uses thereof in immunotherapy

US Patent 12398187 · Granted Aug 26, 2025

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Immune cells comprising truncated NKG2D chimeric receptors2025
Immune cells comprising truncated NKG2D chimeric receptors2025
Immune cells comprising truncated NKG2D chimeric receptors2025
Immune cells comprising truncated NKG2D chimeric receptors2025
Genetically modified natural killer cells for CD70-directed cancer immunotherapy2024
Genetically modified natural killer cells for CD70-directed cancer immunotherapy2024
Genetically modified natural killer cells for CD70-directed cancer immunotherapy2024
Genetically modified natural killer cells for CD70-directed cancer immunotherapy2024
Gene expression markers for predicting overall survival in subjects treated with2024
Interleukin-10 production of antigen-specific CD8+ T cells and methods of use of2023
Methods of using interleukin-10 for treating diseases and disorders2022
Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immun2022